Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Outlook Therapeutics, Inc.ONS · Entity 608 | SVP Bus. Strat. & Dev. | October 22, 2018 | October 24, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Outlook Therapeutics, Inc.
Report date October 22, 2018 · Filed October 24, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.90 · Expires 2028-10-22 | Direct | 200,000 |
Reported balance
After 2018-10-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-10-22 · Grant · Acquired 200,000 · Balance 200,000 F1: The shares underlying the option shall vest in four equal installments beginning on October 22, 2019 such that the option shall be vested in full on October 22, 2022, subject to the Reporting Person providing continuous service to the Issuer on each such date. Vesting may be accelerated in certain circumstances as provided in the Issuer's 2015 Equity Incentive Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying the option shall vest in four equal installments beginning on October 22, 2019 such that the option shall be vested in full on October 22, 2022, subject to the Reporting Person providing continuous service to the Issuer on each such date. Vesting may be accelerated in certain circumstances as provided in the Issuer's 2015 Equity Incentive Plan.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Sonnet BioTherapeutics Holdings, Inc.
Report date December 02, 2025 · Filed December 04, 2025
Section 16 reporting ended · disclosed 2025-12-04. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-12-02 transaction · row 1
1 source rowRow 1 · 2025-12-02 · Disposition to issuer · Disposed 6,446 · Balance 0 F1: On December 2, 2025, pursuant to the Business Combination Agreement (the "BCA"), dated July 11, 2025, by and among Sonnet BioTherapeutics Holdings, Inc. (the "Company"), Rorschach I LLC ("Rorschach"), Hyperliquid Strategies Inc ("HSI"), TBS Merger Sub Inc ("Company Merger Sub") and Rorschach Merger Sub, LLC ("Rorschach Merger Sub"), Rorschach Merger Sub merged with and into Rorschach with Rorschach surviving the merger as a direct wholly owned subsidiary of HSI and immediately following such merger, Company Merger Sub merged with and into the Company with the Company surviving the merger as a direct wholly owned subsidiary of HSI (the "Company Merger"). F2: (Continued from footnote 1) Includes (i) 6,000 restricted stock units granted on July 11, 2025 which, as a result of the Company Merger, vested at the Effective Time and (ii) 446 vested restricted stock units held by the Reporting Person at the Effective Time. Pursuant to the BCA, each restricted stock unit was exchanged at the Effective Time for (i) one-fifth of a share of HSI Common Stock and (ii) one CVR. F3: All amounts reflect the Company's 1:22 reverse stock split effective as of August 31, 2023 and 1:8 reverse stock split effective as of September 30, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: On December 2, 2025, pursuant to the Business Combination Agreement (the "BCA"), dated July 11, 2025, by and among Sonnet BioTherapeutics Holdings, Inc. (the "Company"), Rorschach I LLC ("Rorschach"), Hyperliquid Strategies Inc ("HSI"), TBS Merger Sub Inc ("Company Merger Sub") and Rorschach Merger Sub, LLC ("Rorschach Merger Sub"), Rorschach Merger Sub merged with and into Rorschach with Rorschach surviving the merger as a direct wholly owned subsidiary of HSI and immediately following such merger, Company Merger Sub merged with and into the Company with the Company surviving the merger as a direct wholly owned subsidiary of HSI (the "Company Merger").
F2: (Continued from footnote 1) Includes (i) 6,000 restricted stock units granted on July 11, 2025 which, as a result of the Company Merger, vested at the Effective Time and (ii) 446 vested restricted stock units held by the Reporting Person at the Effective Time. Pursuant to the BCA, each restricted stock unit was exchanged at the Effective Time for (i) one-fifth of a share of HSI Common Stock and (ii) one CVR.
F3: All amounts reflect the Company's 1:22 reverse stock split effective as of August 31, 2023 and 1:8 reverse stock split effective as of September 30, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 02, 2025 Filed Dec 4, 2025 02:15 UTC | Sonnet BioTherapeutics Holdings, Inc. SONN · Entity 72220 | Disposition to issuerCommon Stock | 6,446 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-25-026069 · ownership.xml · nonDerivative · entry 1 MCANDREW STEPHEN J · CIK 0001227041 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: On December 2, 2025, pursuant to the Business Combination Agreement (the "BCA"), dated July 11, 2025, by and among Sonnet BioTherapeutics Holdings, Inc. (the "Company"), Rorschach I LLC ("Rorschach"), Hyperliquid Strategies Inc ("HSI"), TBS Merger Sub Inc ("Company Merger Sub") and Rorschach Merger Sub, LLC ("Rorschach Merger Sub"), Rorschach Merger Sub merged with and into Rorschach with Rorschach surviving the merger as a direct wholly owned subsidiary of HSI and immediately following such merger, Company Merger Sub merged with and into the Company with the Company surviving the merger as a direct wholly owned subsidiary of HSI (the "Company Merger"). F2 · shares: (Continued from footnote 1) Includes (i) 6,000 restricted stock units granted on July 11, 2025 which, as a result of the Company Merger, vested at the Effective Time and (ii) 446 vested restricted stock units held by the Reporting Person at the Effective Time. Pursuant to the BCA, each restricted stock unit was exchanged at the Effective Time for (i) one-fifth of a share of HSI Common Stock and (ii) one CVR. F3 · shares: All amounts reflect the Company's 1:22 reverse stock split effective as of August 31, 2023 and 1:8 reverse stock split effective as of September 30, 2024. F1 · price: On December 2, 2025, pursuant to the Business Combination Agreement (the "BCA"), dated July 11, 2025, by and among Sonnet BioTherapeutics Holdings, Inc. (the "Company"), Rorschach I LLC ("Rorschach"), Hyperliquid Strategies Inc ("HSI"), TBS Merger Sub Inc ("Company Merger Sub") and Rorschach Merger Sub, LLC ("Rorschach Merger Sub"), Rorschach Merger Sub merged with and into Rorschach with Rorschach surviving the merger as a direct wholly owned subsidiary of HSI and immediately following such merger, Company Merger Sub merged with and into the Company with the Company surviving the merger as a direct wholly owned subsidiary of HSI (the "Company Merger"). F2 · price: (Continued from footnote 1) Includes (i) 6,000 restricted stock units granted on July 11, 2025 which, as a result of the Company Merger, vested at the Effective Time and (ii) 446 vested restricted stock units held by the Reporting Person at the Effective Time. Pursuant to the BCA, each restricted stock unit was exchanged at the Effective Time for (i) one-fifth of a share of HSI Common Stock and (ii) one CVR. Read SEC document |
| July 11, 2025 Filed Jul 15, 2025 23:35 UTC | Sonnet BioTherapeutics Holdings, Inc. SONN · Entity 72220 | GrantCommon Stock | 6,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001641172-25-019782 · ownership.xml · nonDerivative · entry 1 MCANDREW STEPHEN J · CIK 0001227041 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,446 F1 · price: On July 11, 2025, the Reporting Person was granted 6,000 restricted stock units, which will be settled in shares of common stock, par value $0.0001. The restricted stock units vest as to 100% of the restricted stock units on the earlier of (i) January 8, 2026, or (ii) the date of a "Change in Control" (as defined under the Issuer's 2020 Omnibus Equity Incentive Plan). F2 · balance_after: Includes unvested restricted stock units. F3 · balance_after: All amounts reflect the Issuer's 1:22 reverse stock split effective as of August 31, 2023 and 1:8 reverse stock split effective as of September 30, 2024. Read SEC document |
| October 22, 2018 Filed Oct 24, 2018 17:02 UTC | Outlook Therapeutics, Inc. ONS · Entity 608 | GrantStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $0.90 | $0.00 |
DisclosureSEC source: 0001209191-18-056074 · doc4.xml · derivative · entry 1 MCANDREW STEPHEN J · CIK 0001227041 · SVP Bus. Strat. & Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2028-10-22 F1 · derivative.exercise_date: The shares underlying the option shall vest in four equal installments beginning on October 22, 2019 such that the option shall be vested in full on October 22, 2022, subject to the Reporting Person providing continuous service to the Issuer on each such date. Vesting may be accelerated in certain circumstances as provided in the Issuer's 2015 Equity Incentive Plan. Read SEC document |
| June 15, 2018 Filed Jun 19, 2018 18:11 UTC | Outlook Therapeutics, Inc. ONS · Entity 608 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $0.90 | $0.00 |
DisclosureSEC source: 0001209191-18-038655 · doc4.xml · derivative · entry 1 MCANDREW STEPHEN J · CIK 0001227041 · SVP Bus. Strat. & Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2028-06-15 F1 · derivative.exercise_date: The shares underlying the option shall vest in three equal installments beginning on June 15, 2019 such that the option shall be vested in full on June 15, 2021, subject to the Reporting Person providing continuous service to the Issuer on each such date. Read SEC document |
| December 22, 2017 Filed Dec 26, 2017 17:05 UTC | Outlook Therapeutics, Inc. ONS · Entity 608 | SaleCommon Stock | 15,705 | $1.13 | $17,746.65 |
DisclosureSEC source: 0001209191-17-067232 · doc4.xml · nonDerivative · entry 1 MCANDREW STEPHEN J · CIK 0001227041 · SVP Bus. Strat. & Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,899 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units ("RSUs"). This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person. F2 · balance_after: Includes shares of common stock underlying RSUs reported on the Reporting Person's Form 4 filed with the Securities and Exchange Commission on December 22, 2016. The vesting of RSUs was accelerated such that 100% of the shares underlying the RSU vested on December 21, 2017. Read SEC document |
| December 21, 2016 Filed Dec 22, 2016 18:05 UTC | Outlook Therapeutics, Inc. ONS · Entity 608 | GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-156583 · doc4.xml · nonDerivative · entry 1 MCANDREW STEPHEN J · CIK 0001227041 · SVP Bus. Strat. & Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,604 F1 · security: This security represents restricted stock units. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. F2 · shares: The shares underlying this restricted stock unit award vests in two equal installments on each of December 21, 2017 and December 21, 2018, in each case subject to the Reporting Person's continuous service to the Issuer through each such date. In addition, 100% of the shares underlying the restricted stock unit award will satisfy the time-based vesting restrictions upon the occurrence of a change of control, subject to continued service through such event. Read SEC document |
| November 11, 2016 Filed Nov 14, 2016 18:20 UTC | Outlook Therapeutics, Inc. ONS · Entity 608 | SaleCommon Stock | 21,367 | $3.75 | $80,126.25 |
DisclosureSEC source: 0001214659-16-014639 · marketforms-36878.xml · nonDerivative · entry 3 MCANDREW STEPHEN J · CIK 0001227041 · SVP Bus. Strat. & Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,604 F4 · shares: Represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of restricted stock units on November 9, 2016. This sale is mandated by the Issuer's election under its equity incentive plans to require the reporting person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the reporting person. Read SEC document |
| November 09, 2016 Filed Nov 14, 2016 18:20 UTC | Outlook Therapeutics, Inc. ONS · Entity 608 | Exercise / conversionCommon Stock | 57,971 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001214659-16-014639 · marketforms-36878.xml · nonDerivative · entry 2 MCANDREW STEPHEN J · CIK 0001227041 · SVP Bus. Strat. & Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,971 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each restricted stock unit ("RSU") represents the right to receive, at settlement, one (1) share of the Issuer's common stock. Read SEC document |
| November 09, 2016 Filed Nov 14, 2016 18:20 UTC | Outlook Therapeutics, Inc. ONS · Entity 608 | ConversionRestricted Stock Units | 57,971 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-16-014639 · marketforms-36878.xml · nonDerivative · entry 1 MCANDREW STEPHEN J · CIK 0001227041 · SVP Bus. Strat. & Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Granted pursuant to the Issuer's 2015 Equity Incentive Plan. F2 · shares: Each restricted stock unit ("RSU") represents the right to receive, at settlement, one (1) share of the Issuer's common stock. F3 · shares: The RSUs vest upon the first to occur of (x) a change of control as defined in the award agreement and (y) the expiration of the 6 month lock-up period following the Issuer's initial public offering, in each case subject to continued service through such event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.